Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Preferred Stock Liabilities (2019)

Historic Preferred Stock Liabilities for Nurix Therapeutics (NRIX) over the last 1 years, with Q4 2019 value amounting to $48.2 million.

  • Nurix Therapeutics' Preferred Stock Liabilities changed N/A to $48.2 million in Q4 2019 from the same period last year, while for Nov 2019 it was $48.2 million, marking a year-over-year change of. This contributed to the annual value of $48.2 million for FY2019, which is N/A changed from last year.
  • Per Nurix Therapeutics' latest filing, its Preferred Stock Liabilities stood at $48.2 million for Q4 2019.
  • Nurix Therapeutics' 5-year Preferred Stock Liabilities high stood at $48.2 million for Q3 2019, and its period low was $48.2 million during Q3 2019.